Susan C. Low

3.8k total citations
29 papers, 1.6k citations indexed

About

Susan C. Low is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Susan C. Low has authored 29 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 12 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Susan C. Low's work include Monoclonal and Polyclonal Antibodies Research (7 papers), Glycosylation and Glycoproteins Research (5 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Susan C. Low is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), Glycosylation and Glycoproteins Research (5 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Susan C. Low collaborates with scholars based in United States, United Kingdom and Switzerland. Susan C. Low's co-authors include Marla J. Berry, Alan J. Bitonti, Jennifer Dumont, John W. Harney, Robert Peters, George D. Kamphaus, Thomas J. Reidy, Donald M. Parsons, Timothy C. Nichols and Stephen E. Zale and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Blood.

In The Last Decade

Susan C. Low

26 papers receiving 1.6k citations

Peers

Susan C. Low
Susan C. Low
Citations per year, relative to Susan C. Low Susan C. Low (= 1×) peers V. B. Vasilyev

Countries citing papers authored by Susan C. Low

Since Specialization
Citations

This map shows the geographic impact of Susan C. Low's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan C. Low with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan C. Low more than expected).

Fields of papers citing papers by Susan C. Low

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan C. Low. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan C. Low. The network helps show where Susan C. Low may publish in the future.

Co-authorship network of co-authors of Susan C. Low

This figure shows the co-authorship network connecting the top 25 collaborators of Susan C. Low. A scholar is included among the top collaborators of Susan C. Low based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan C. Low. Susan C. Low is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fishman, Jay A., Joseph El Khoury, Tatsuo Kawai, et al.. (2025). Infectious disease surveillance and management in clinical xenotransplantation: Experience with the first human porcine kidney transplant. American Journal of Transplantation. 25(11). 2451–2457. 1 indexed citations
2.
Karadagi, Ahmad, Takayuki Hirose, Ivy A. Rosales, et al.. (2023). 412.1: Long-term (2 years) survival of porcine to nonhuman primate life-sustaining kidney xenotransplantation. Transplantation. 107(10S2). 173–173.
3.
Hoff, Daniel D. Von, Monica Mita, Ramesh K. Ramanathan, et al.. (2016). Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(13). 3157–3163. 215 indexed citations
4.
Song, Young Ho, Hong Wang, James J. Nolan, et al.. (2016). A novel in situ hydrophobic ion pairing (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system. Journal of Controlled Release. 229. 106–119. 73 indexed citations
5.
Low, Susan C.. (2015). Signal Grass (Brachiaria decumbens) Toxicity in Grazing Ruminants. Agriculture. 5(4). 971–990. 25 indexed citations
6.
Lam, Michael Hon‐Wah, Young Ho Song, Hong Wang, et al.. (2015). Abstract C197: Accurins improve the pharmacokinetics, pharmacodynamics, tolerability and anti-tumor activity of the AKT inhibitor MK-2206. Molecular Cancer Therapeutics. 14(12_Supplement_2). C197–C197.
7.
Arnold, Kristen, et al.. (2015). Abstract C184: BIND-510 improves the pharmacokinetics, tolerability, tumor accumulation and tumor growth inhibition in preclinical models of cancer compared to vincristine sulfate. Molecular Cancer Therapeutics. 14(12_Supplement_2). C184–C184. 3 indexed citations
8.
Barry, Simon T., Elaine Cadogan, Rajesh Odedra, et al.. (2014). Abstract 5409: AZD1152-hQPA Accurins: Nanoparticle formulations showing extended release and the potential for improved therapeutic index. Cancer Research. 74(19_Supplement). 5409–5409. 2 indexed citations
9.
Dumont, Jennifer, Tongyao Liu, Susan C. Low, et al.. (2012). Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood. 119(13). 3024–3030. 115 indexed citations
10.
Vallée, Sébastien, Thomas J. Reidy, Sandra Walker, et al.. (2011). Pulmonary Administration of Interferon Beta-1a-Fc Fusion Protein in Non-Human Primates Using an Immunoglobulin Transport Pathway. Journal of Interferon & Cytokine Research. 32(4). 178–184. 20 indexed citations
11.
Mezo, Adam R., et al.. (2011). PEGylation enhances the therapeutic potential of peptide antagonists of the neonatal Fc receptor, FcRn. Bioorganic & Medicinal Chemistry Letters. 21(21). 6332–6335. 7 indexed citations
12.
Peters, Robert, Susan C. Low, George D. Kamphaus, et al.. (2010). Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood. 115(10). 2057–2064. 148 indexed citations
13.
Low, Susan C. & Adam R. Mezo. (2009). Inhibitors of the FcRn:IgG Protein–Protein Interaction. The AAPS Journal. 11(3). 432–4. 14 indexed citations
14.
Mezo, Adam R., Kevin McDonnell, Cristina A. Tan Hehir, et al.. (2008). Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn. Proceedings of the National Academy of Sciences. 105(7). 2337–2342. 86 indexed citations
15.
Dumont, Jennifer, Susan C. Low, Robert Peters, & Alan J. Bitonti. (2006). Monomeric Fc Fusions. BioDrugs. 20(3). 151–160. 96 indexed citations
16.
Bitonti, Alan J., Jennifer Dumont, Susan C. Low, et al.. (2004). Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proceedings of the National Academy of Sciences. 101(26). 9763–9768. 177 indexed citations
17.
Berry, Marla J., Rosa M. Tujebajeva, Paul R. Copeland, et al.. (2001). Selenocysteine incorporation directed from the 3′UTR: Characterization of eukaryotic EFsec and mechanistic implications. BioFactors. 14(1-4). 17–24. 52 indexed citations
18.
Low, Susan C. & Marla J. Berry. (1996). Knowing when not to stop: selenocysteine incorporation in eukaryotes. Trends in Biochemical Sciences. 21(6). 203–208. 360 indexed citations
19.
Low, Susan C., John W. Harney, & Marla J. Berry. (1995). Cloning and Functional Characterization of Human Selenophosphate Synthetase, an Essential Component of Selenoprotein Synthesis. Journal of Biological Chemistry. 270(37). 21659–21664. 145 indexed citations
20.
Low, Susan C., Marie‐Pierre Moisan, June Noble, Christopher R.W. Edwards, & Jonathan R. Seckl. (1994). Glucocorticoids Regulate Hippocampal 11β‐Hydroxysteroid Dehydrogenase Activity and Gene Expression in vivo in the Rat. Journal of Neuroendocrinology. 6(3). 285–290. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026